US 11,926,859 B2
Methods and means for the production of Ig-like molecules
Cornelis Adriaan De Kruif, Utrecht (NL); Linda Johanna Aleida Hendriks, Utrecht (NL); and Ton Logtenberg, Utrecht (NL)
Assigned to Merus N.V., Utrecht (NL)
Filed by Merus N.V., Utrecht (NL)
Filed on May 16, 2023, as Appl. No. 18/318,507.
Application 18/318,507 is a continuation of application No. 16/934,925, filed on Jul. 21, 2020.
Application 16/934,925 is a continuation of application No. 16/417,379, filed on May 20, 2019, granted, now 10,752,929, issued on Aug. 25, 2020.
Application 16/417,379 is a continuation of application No. 15/155,743, filed on May 16, 2016, granted, now 10,329,596, issued on Jun. 25, 2019.
Application 15/155,743 is a continuation of application No. 14/081,848, filed on Nov. 15, 2013, granted, now 9,358,286, issued on Jun. 7, 2016.
Application 14/081,848 is a continuation of application No. 13/866,747, filed on Apr. 19, 2013, granted, now 9,248,181, issued on Feb. 2, 2016.
Claims priority of provisional application 61/635,935, filed on Apr. 20, 2012.
Prior Publication US 2023/0340556 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/00 (2006.01); A61K 39/395 (2006.01); A61K 39/40 (2006.01); C07K 16/12 (2006.01); C07K 16/18 (2006.01); C07K 16/26 (2006.01); C07K 16/28 (2006.01); C07K 16/36 (2006.01); C07K 16/46 (2006.01); C12P 21/00 (2006.01); A61K 39/00 (2006.01)
CPC C12P 21/005 (2013.01) [A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 39/40 (2013.01); C07K 16/12 (2013.01); C07K 16/1278 (2013.01); C07K 16/1282 (2013.01); C07K 16/18 (2013.01); C07K 16/26 (2013.01); C07K 16/28 (2013.01); C07K 16/2809 (2013.01); C07K 16/283 (2013.01); C07K 16/2866 (2013.01); C07K 16/2896 (2013.01); C07K 16/36 (2013.01); C07K 16/468 (2013.01); A61K 2039/507 (2013.01); C07K 2317/14 (2013.01); C07K 2317/31 (2013.01); C07K 2317/526 (2013.01); C07K 2317/56 (2013.01); C07K 2317/94 (2013.01)] 7 Claims
 
1. A heterodimeric antibody comprising a first human CH3 domain comprising a positively charged amino acid residue at position 364 according to the EU numbering system, and a second human CH3 domain comprising a negatively charged amino acid residue at position 368 according to the EU numbering system.